With regard to treatments and therapies for rare diseases (known as orphan drugs): (a) how many orphan drugs were granted market authorization by Health Canada between May, 2013, and June, 2017; (b) how many orphan drugs were issued market authorization between November 4, 2015, and June 20, 2017; and (c) what are the names of all orphan drugs granted market authorization in both (a) and (b)?
In the House of Commons on October 6th, 2017. See this statement in context.